The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Ipilimumab is a monoclonal antibody, more specifically a fully humanized IgG1 antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint.
The global Ipilimumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Ipilimumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ipilimumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Ipilimumab include Gilead, BMS, Ono, Roche, Prestige BioPharma, Avacta, Baxter and Shenyang Sansheng Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Ipilimumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ipilimumab.
Report Scope
The Ipilimumab market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ipilimumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ipilimumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
BMS
Ono
Roche
Prestige BioPharma
Avacta
Baxter
Shenyang Sansheng Pharmaceutical
Segment by Type
PD - L1 Antagonists
CTLA4 Antagonists
Immunocheckpoint Inhibitors
Other
Segment by Application
Cancer
Melanoma
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ipilimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ipilimumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Ipilimumab is a monoclonal antibody, more specifically a fully humanized IgG1 antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint.
The global Ipilimumab market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Ipilimumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ipilimumab is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Ipilimumab include Gilead, BMS, Ono, Roche, Prestige BioPharma, Avacta, Baxter and Shenyang Sansheng Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Ipilimumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ipilimumab.
Report Scope
The Ipilimumab market size, estimations, and forecasts are provided in terms of sales volume (KG) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ipilimumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ipilimumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
BMS
Ono
Roche
Prestige BioPharma
Avacta
Baxter
Shenyang Sansheng Pharmaceutical
Segment by Type
PD - L1 Antagonists
CTLA4 Antagonists
Immunocheckpoint Inhibitors
Other
Segment by Application
Cancer
Melanoma
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ipilimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ipilimumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Ipilimumab Market Overview
1.1 Product Overview and Scope of Ipilimumab
1.2 Ipilimumab Segment by Type
1.2.1 Global Ipilimumab Market Value Comparison by Type (2024-2030)
1.2.2 PD - L1 Antagonists
1.2.3 CTLA4 Antagonists
1.2.4 Immunocheckpoint Inhibitors
1.2.5 Other
1.3 Ipilimumab Segment by Application
1.3.1 Global Ipilimumab Market Value by Application: (2024-2030)
1.3.2 Cancer
1.3.3 Melanoma
1.4 Global Ipilimumab Market Size Estimates and Forecasts
1.4.1 Global Ipilimumab Revenue 2019-2030
1.4.2 Global Ipilimumab Sales 2019-2030
1.4.3 Global Ipilimumab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Ipilimumab Market Competition by Manufacturers
2.1 Global Ipilimumab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Ipilimumab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Ipilimumab Average Price by Manufacturers (2019-2024)
2.4 Global Ipilimumab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ipilimumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ipilimumab, Product Type & Application
2.7 Ipilimumab Market Competitive Situation and Trends
2.7.1 Ipilimumab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ipilimumab Players Market Share by Revenue
2.7.3 Global Ipilimumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ipilimumab Retrospective Market Scenario by Region
3.1 Global Ipilimumab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Ipilimumab Global Ipilimumab Sales by Region: 2019-2030
3.2.1 Global Ipilimumab Sales by Region: 2019-2024
3.2.2 Global Ipilimumab Sales by Region: 2025-2030
3.3 Global Ipilimumab Global Ipilimumab Revenue by Region: 2019-2030
3.3.1 Global Ipilimumab Revenue by Region: 2019-2024
3.3.2 Global Ipilimumab Revenue by Region: 2025-2030
3.4 North America Ipilimumab Market Facts & Figures by Country
3.4.1 North America Ipilimumab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Ipilimumab Sales by Country (2019-2030)
3.4.3 North America Ipilimumab Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Ipilimumab Market Facts & Figures by Country
3.5.1 Europe Ipilimumab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Ipilimumab Sales by Country (2019-2030)
3.5.3 Europe Ipilimumab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ipilimumab Market Facts & Figures by Country
3.6.1 Asia Pacific Ipilimumab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Ipilimumab Sales by Country (2019-2030)
3.6.3 Asia Pacific Ipilimumab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Ipilimumab Market Facts & Figures by Country
3.7.1 Latin America Ipilimumab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Ipilimumab Sales by Country (2019-2030)
3.7.3 Latin America Ipilimumab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ipilimumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Ipilimumab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Ipilimumab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Ipilimumab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ipilimumab Sales by Type (2019-2030)
4.1.1 Global Ipilimumab Sales by Type (2019-2024)
4.1.2 Global Ipilimumab Sales by Type (2025-2030)
4.1.3 Global Ipilimumab Sales Market Share by Type (2019-2030)
4.2 Global Ipilimumab Revenue by Type (2019-2030)
4.2.1 Global Ipilimumab Revenue by Type (2019-2024)
4.2.2 Global Ipilimumab Revenue by Type (2025-2030)
4.2.3 Global Ipilimumab Revenue Market Share by Type (2019-2030)
4.3 Global Ipilimumab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Ipilimumab Sales by Application (2019-2030)
5.1.1 Global Ipilimumab Sales by Application (2019-2024)
5.1.2 Global Ipilimumab Sales by Application (2025-2030)
5.1.3 Global Ipilimumab Sales Market Share by Application (2019-2030)
5.2 Global Ipilimumab Revenue by Application (2019-2030)
5.2.1 Global Ipilimumab Revenue by Application (2019-2024)
5.2.2 Global Ipilimumab Revenue by Application (2025-2030)
5.2.3 Global Ipilimumab Revenue Market Share by Application (2019-2030)
5.3 Global Ipilimumab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead
6.1.1 Gilead Corporation Information
6.1.2 Gilead Description and Business Overview
6.1.3 Gilead Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Ipilimumab Product Portfolio
6.1.5 Gilead Recent Developments/Updates
6.2 BMS
6.2.1 BMS Corporation Information
6.2.2 BMS Description and Business Overview
6.2.3 BMS Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BMS Ipilimumab Product Portfolio
6.2.5 BMS Recent Developments/Updates
6.3 Ono
6.3.1 Ono Corporation Information
6.3.2 Ono Description and Business Overview
6.3.3 Ono Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Ono Ipilimumab Product Portfolio
6.3.5 Ono Recent Developments/Updates
6.4 Roche
6.4.1 Roche Corporation Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche Ipilimumab Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Prestige BioPharma
6.5.1 Prestige BioPharma Corporation Information
6.5.2 Prestige BioPharma Description and Business Overview
6.5.3 Prestige BioPharma Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Prestige BioPharma Ipilimumab Product Portfolio
6.5.5 Prestige BioPharma Recent Developments/Updates
6.6 Avacta
6.6.1 Avacta Corporation Information
6.6.2 Avacta Description and Business Overview
6.6.3 Avacta Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Avacta Ipilimumab Product Portfolio
6.6.5 Avacta Recent Developments/Updates
6.7 Baxter
6.6.1 Baxter Corporation Information
6.6.2 Baxter Description and Business Overview
6.6.3 Baxter Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Baxter Ipilimumab Product Portfolio
6.7.5 Baxter Recent Developments/Updates
6.8 Shenyang Sansheng Pharmaceutical
6.8.1 Shenyang Sansheng Pharmaceutical Corporation Information
6.8.2 Shenyang Sansheng Pharmaceutical Description and Business Overview
6.8.3 Shenyang Sansheng Pharmaceutical Ipilimumab Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shenyang Sansheng Pharmaceutical Ipilimumab Product Portfolio
6.8.5 Shenyang Sansheng Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ipilimumab Industry Chain Analysis
7.2 Ipilimumab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ipilimumab Production Mode & Process
7.4 Ipilimumab Sales and Marketing
7.4.1 Ipilimumab Sales Channels
7.4.2 Ipilimumab Distributors
7.5 Ipilimumab Customers
8 Ipilimumab Market Dynamics
8.1 Ipilimumab Industry Trends
8.2 Ipilimumab Market Drivers
8.3 Ipilimumab Market Challenges
8.4 Ipilimumab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Ipilimumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Ipilimumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Ipilimumab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Ipilimumab Sales (KG) of Key Manufacturers (2019-2024)
Table 5. Global Ipilimumab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Ipilimumab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Ipilimumab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Ipilimumab Average Price (US$/G) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Ipilimumab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Ipilimumab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Ipilimumab, Product Type & Application
Table 12. Global Key Manufacturers of Ipilimumab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Ipilimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ipilimumab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Ipilimumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Ipilimumab Sales by Region (2019-2024) & (KG)
Table 18. Global Ipilimumab Sales Market Share by Region (2019-2024)
Table 19. Global Ipilimumab Sales by Region (2025-2030) & (KG)
Table 20. Global Ipilimumab Sales Market Share by Region (2025-2030)
Table 21. Global Ipilimumab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Ipilimumab Revenue Market Share by Region (2019-2024)
Table 23. Global Ipilimumab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Ipilimumab Revenue Market Share by Region (2025-2030)
Table 25. North America Ipilimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Ipilimumab Sales by Country (2019-2024) & (KG)
Table 27. North America Ipilimumab Sales by Country (2025-2030) & (KG)
Table 28. North America Ipilimumab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Ipilimumab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Ipilimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Ipilimumab Sales by Country (2019-2024) & (KG)
Table 32. Europe Ipilimumab Sales by Country (2025-2030) & (KG)
Table 33. Europe Ipilimumab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Ipilimumab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Ipilimumab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Ipilimumab Sales by Region (2019-2024) & (KG)
Table 37. Asia Pacific Ipilimumab Sales by Region (2025-2030) & (KG)
Table 38. Asia Pacific Ipilimumab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Ipilimumab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Ipilimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Ipilimumab Sales by Country (2019-2024) & (KG)
Table 42. Latin America Ipilimumab Sales by Country (2025-2030) & (KG)
Table 43. Latin America Ipilimumab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Ipilimumab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Ipilimumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Ipilimumab Sales by Country (2019-2024) & (KG)
Table 47. Middle East & Africa Ipilimumab Sales by Country (2025-2030) & (KG)
Table 48. Middle East & Africa Ipilimumab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Ipilimumab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Ipilimumab Sales (KG) by Type (2019-2024)
Table 51. Global Ipilimumab Sales (KG) by Type (2025-2030)
Table 52. Global Ipilimumab Sales Market Share by Type (2019-2024)
Table 53. Global Ipilimumab Sales Market Share by Type (2025-2030)
Table 54. Global Ipilimumab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Ipilimumab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Ipilimumab Revenue Market Share by Type (2019-2024)
Table 57. Global Ipilimumab Revenue Market Share by Type (2025-2030)
Table 58. Global Ipilimumab Price (US$/G) by Type (2019-2024)
Table 59. Global Ipilimumab Price (US$/G) by Type (2025-2030)
Table 60. Global Ipilimumab Sales (KG) by Application (2019-2024)
Table 61. Global Ipilimumab Sales (KG) by Application (2025-2030)
Table 62. Global Ipilimumab Sales Market Share by Application (2019-2024)
Table 63. Global Ipilimumab Sales Market Share by Application (2025-2030)
Table 64. Global Ipilimumab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Ipilimumab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Ipilimumab Revenue Market Share by Application (2019-2024)
Table 67. Global Ipilimumab Revenue Market Share by Application (2025-2030)
Table 68. Global Ipilimumab Price (US$/G) by Application (2019-2024)
Table 69. Global Ipilimumab Price (US$/G) by Application (2025-2030)
Table 70. Gilead Corporation Information
Table 71. Gilead Description and Business Overview
Table 72. Gilead Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 73. Gilead Ipilimumab Product
Table 74. Gilead Recent Developments/Updates
Table 75. BMS Corporation Information
Table 76. BMS Description and Business Overview
Table 77. BMS Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 78. BMS Ipilimumab Product
Table 79. BMS Recent Developments/Updates
Table 80. Ono Corporation Information
Table 81. Ono Description and Business Overview
Table 82. Ono Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 83. Ono Ipilimumab Product
Table 84. Ono Recent Developments/Updates
Table 85. Roche Corporation Information
Table 86. Roche Description and Business Overview
Table 87. Roche Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 88. Roche Ipilimumab Product
Table 89. Roche Recent Developments/Updates
Table 90. Prestige BioPharma Corporation Information
Table 91. Prestige BioPharma Description and Business Overview
Table 92. Prestige BioPharma Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 93. Prestige BioPharma Ipilimumab Product
Table 94. Prestige BioPharma Recent Developments/Updates
Table 95. Avacta Corporation Information
Table 96. Avacta Description and Business Overview
Table 97. Avacta Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 98. Avacta Ipilimumab Product
Table 99. Avacta Recent Developments/Updates
Table 100. Baxter Corporation Information
Table 101. Baxter Description and Business Overview
Table 102. Baxter Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 103. Baxter Ipilimumab Product
Table 104. Baxter Recent Developments/Updates
Table 105. Shenyang Sansheng Pharmaceutical Corporation Information
Table 106. Shenyang Sansheng Pharmaceutical Description and Business Overview
Table 107. Shenyang Sansheng Pharmaceutical Ipilimumab Sales (KG), Revenue (US$ Million), Price (US$/G) and Gross Margin (2019-2024)
Table 108. Shenyang Sansheng Pharmaceutical Ipilimumab Product
Table 109. Shenyang Sansheng Pharmaceutical Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Ipilimumab Distributors List
Table 113. Ipilimumab Customers List
Table 114. Ipilimumab Market Trends
Table 115. Ipilimumab Market Drivers
Table 116. Ipilimumab Market Challenges
Table 117. Ipilimumab Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Ipilimumab
Figure 2. Global Ipilimumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Ipilimumab Market Share by Type in 2023 & 2030
Figure 4. PD - L1 Antagonists Product Picture
Figure 5. CTLA4 Antagonists Product Picture
Figure 6. Immunocheckpoint Inhibitors Product Picture
Figure 7. Other Product Picture
Figure 8. Global Ipilimumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Ipilimumab Market Share by Application in 2023 & 2030
Figure 10. Cancer
Figure 11. Melanoma
Figure 12. Global Ipilimumab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Ipilimumab Market Size (2019-2030) & (US$ Million)
Figure 14. Global Ipilimumab Sales (2019-2030) & (KG)
Figure 15. Global Ipilimumab Average Price (US$/G) & (2019-2030)
Figure 16. Ipilimumab Report Years Considered
Figure 17. Ipilimumab Sales Share by Manufacturers in 2023
Figure 18. Global Ipilimumab Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Ipilimumab Players: Market Share by Revenue in 2023
Figure 20. Ipilimumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Ipilimumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Ipilimumab Sales Market Share by Country (2019-2030)
Figure 23. North America Ipilimumab Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Ipilimumab Sales Market Share by Country (2019-2030)
Figure 27. Europe Ipilimumab Revenue Market Share by Country (2019-2030)
Figure 28. Germany Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Ipilimumab Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Ipilimumab Revenue Market Share by Region (2019-2030)
Figure 35. China Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Ipilimumab Sales Market Share by Country (2019-2030)
Figure 46. Latin America Ipilimumab Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Ipilimumab Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Ipilimumab Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Ipilimumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Ipilimumab by Type (2019-2030)
Figure 56. Global Revenue Market Share of Ipilimumab by Type (2019-2030)
Figure 57. Global Ipilimumab Price (US$/G) by Type (2019-2030)
Figure 58. Global Sales Market Share of Ipilimumab by Application (2019-2030)
Figure 59. Global Revenue Market Share of Ipilimumab by Application (2019-2030)
Figure 60. Global Ipilimumab Price (US$/G) by Application (2019-2030)
Figure 61. Ipilimumab Value Chain
Figure 62. Ipilimumab Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
